Wysocki NA, et al. - Since the comparative safety of leaving tPA (tissue-type plasminogen activator)-treated patients at a presenting (spoke) hospital (drip-and-stay) or transferring patients to a central treating (hub) hospital (drip-and-ship) is not established, researchers compared outcomes between drip-and-ship and drip-and-stay patients treated with tPA through telemedicine. Between September 2015 and December 2016, patients treated with tPA at 17 spoke hospitals were retrospectively identified. According to this retrospective study, no differences were found in measured outcomes between drip-and-ship and drip-and-stay patients treated in the network, although the study might be underpowered to detect small differences. No significant differences were found in the adjusted length of stay, hospital mortality, or discharge disposition.